Followers | 14 |
Posts | 306 |
Boards Moderated | 0 |
Alias Born | 01/17/2021 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, February 15, 2023 8:08:04 PM
DARPA RPM Aims to Speed-Up Production of On-Demand Protein-Based Therapeutics
Agency names performers for Reimagining Protein Manufacturing program
OUTREACH@DARPA.MIL
2/15/2023
Reimaging Protein Manufacturing (RPM)
Department of Defense (DoD) access to critical protein-based therapeutics is limited by the slow pace and substantial costs associated with current protein production methods. The goal of the DARPA Reimaging Protein Manufacturing (RPM) program is to develop tools for distributed, on-demand manufacturing of protein-based drugs, such as antibodies or vaccines, or the proteins required to make them. DARPA has selected performer teams that aim to demonstrate immediate production -- initiated within 24 hours -- of protein products with yields in excess of 500 units per week with correct protein modifications.
“The current process for producing protein-based therapeutics requires more than a year to establish, while still requiring purification and significant infrastructure,” noted RPM program manager, Dr. Michael Feasel. “RPM aims to initiate protein production within 24 hours, eliminating this long lead time. Fast, on-demand distributed manufacturing could make key proteins on a DoD-relevant timeline in operational environments.”
The 50-month RPM program will address two technical areas. Technical Area 1, Production Yield and Time, focuses on protein synthesis technologies for near-immediate manufacture of proteins at high yields. Technical Area 2, Post-Translational Modifications, seeks novel approaches to make necessary modifications to proteins after production, in a controlled manner to ensure that the final product is bioactive and of high quality.
DARPA selected the following research teams, which are pursuing a variety of approaches to meet the challenges of RPM: Ginkgo Bioworks, Inc., Leidos Inc., and Northwestern University.
“In biology, cellular protein production follows a central dogma: DNA makes RNA and RNA makes protein. Cells do this efficiently, but when you engineer cells to make a protein of your choice, the protein production process is much more time consuming,” Feasel said. “RPM aims to remove the cells from the process using cell-free protein synthesis technologies to decrease time to production, increase yield of production, and perform the correct protein modifications.”
DARPA will utilize independent validation and verification partners throughout the program to assess the function, stability, and composition of the proteins produced through a series of field-recognized analytical techniques.
https://www.darpa.mil/news-events/2023-02-15
Recent DNA News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/20/2024 02:51:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/18/2024 02:26:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:14:24 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:12:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:07:16 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/13/2024 02:14:43 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/12/2024 02:31:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/11/2024 02:43:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/10/2024 02:33:14 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/07/2024 02:15:10 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/06/2024 02:03:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 09:06:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 09:04:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/05/2024 02:25:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/04/2024 02:08:43 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 07:39:59 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 06:08:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/31/2024 03:39:48 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/30/2024 02:58:43 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/29/2024 02:45:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 02:18:58 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/24/2024 02:22:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/23/2024 02:02:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/22/2024 01:44:33 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/21/2024 03:02:29 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM